COMMITTED
TO EXCEPTIONAL ACCESS

PAYERS COVER RINVOQ after the trial of 1 TNFi (branded or biosimilar) with greater than 95 percent PREFERRED COMMERCIAL AND MEDICARE PART D COVERAGE. National Commercial and Medicare Part D formulary coverage under the pharmacy benefit as of April 2024 in Adult PsA, RA, AS, and nr-axSpA.

What can PREFERRED COVERAGE mean for your patients?

 

Accessibility

Covered after trial of 1 TNFi ahead of non-preferred products.

Individual plan coverage/benefits may vary and are subject to change.

Affordability

Commercial:

  • Lowest branded copay tier
89 percent.

of Commercial claims for a filled prescription cost patients $5 or less.

§Based upon paid Commercial claims data from national data providers for a filled RINVOQ prescription for RA, PsA, AS and nr-axSpA for the period 01/2023-09/2023, inclusive of savings and redemptions.

Patients' actual out-of-pocket cost may vary depending on their insurance coverage, and eligibility for support programs.

Medicare Part D:

  • Lowest coinsurance formulary tier||

||Copay assistance programs are not available to patients receiving prescription reimbursement under any federal, state or government-funded insurance programs (e.g., Medicare Part D and Medicare Advantage programs) or where prohibited by law or by the patient's health insurance provider.

*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.

Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

Check the Formulary Status for RINVOQ in Your Area

Formulary Zipcode


Select a filter

Choose Indication

Please enter a valid zip code.

Formulary Status Results

  • Plan Name
  • Plan Type
  • Status

Results ends here

Preferred means RINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.

AS=ankylosing spondylitis; nr-axSpA=non-radiographic axial spondyloarthritis; PsA=psoriatic arthritis; RA=rheumatoid arthritis; TNFi=tumor necrosis factor inhibitor.

Additional Resources Are Available to Support Your Patients in Accessing and Receiving Treatment With RINVOQ